Medical Developments International shares on watch following Penthrox update

The Medical Developments International Ltd (ASX:MVP) share price will be on watch today after the release of a Penthrox update…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price will be on watch this morning follow a positive announcement relating to its Penthrox product.

a woman

What is Penthrox?

Penthrox, or the green whistle, is a fast onset, non-opioid analgesic. It is indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures.

It has been used safely and effectively for over 40 years in Australia with more than 5 million units sold.

In recent times the company has been looking at expanding its use, hence today's announcement.

What did Medical Developments International announce?

This morning the healthcare company announced that data across 11 abstracts of studies conducted throughout Europe have demonstrated multiple positive results of Penthrox.

This includes Penthrox demonstrating superiority over intravenous (IV) morphine, paracetamol, ketoprofen, and NSAIDS within a trauma setting.

It also found that Penthrox added to the standard of care (SoC) demonstrates superiority over SoC plus a placebo within a trauma setting.

The product was also successful in dislocation injuries. Its use resulted in reduced time spent in the Emergency Departments, which improves the patient experience and reduces crowding.

The release explains that other studies confirmed previously published data. This includes Penthrox being an efficacious, well tolerated/safe and rapidly acting analgesic in trauma settings.

Another positive was that the studies commonly reported that Penthrox exceeded patient/clinician expectations and/or resulted in a high degree of treatment satisfaction from patients and health care professionals.

The company's CEO, John Sharman, was delighted with the study results.

He said: "We are delighted with the results of these recent European clinical trials demonstrating superiority of Penthrox over Standard of Care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Red buy button on an Apple keyboard with a finger on it.
Broker Notes

Brokers name 3 ASX shares to buy right now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Market News

Why Beetaloo, Fortescue, Orora, and Whitehaven Coal shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Man in a business suit leaps off a boulder in front of a blue sky.
Share Gainers

3 ASX 200 stocks surging 13% to 36% in this shortened trading week

Investors sent these three ASX 200 stocks flying higher following the Easter break. But why?

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Why Amaero, Mesoblast, Telix, and Tivan shares are charging higher today

These shares are ending the week on a high. But why?

Read more »

A young couple stands next to a real estate agent in an empty apartment they are inspecting.
Real Estate Shares

Mirvac shares sink to their lowest level since 2015. Is this ASX property giant back on the radar?

Multi-year lows put Mirvac shares back on investors’ watchlists today.

Read more »

surprised child reading all about asx 200 shares in a newspaper
Share Market News

Why Magellan, Telix and Fortescue shares are grabbing headlines on Friday

Telix, Magellan, and Fortescue shares are catching ASX investor interest today. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
52-Week Lows

Harvey Norman just hit a 52-week low. Is this beaten-down ASX retailer becoming too cheap to ignore?

Harvey Norman sinks to 52-week low as sentiment weakens further.

Read more »

Woman using a pen on a digital stock market chart in an office.
Broker Notes

Could these ASX stocks double by the end of 2026?

These 5 stocks could be undervalued.

Read more »